This enduring educational curriculum targeted for US-based hematologists and hem-oncologists will focus on improving clinicians knowledge and competence regarding the role of bispecific T-cell antibodies for patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least three prior lines of therapy or are triple refractory and how to integrate these therapies in a community setting. As a result of this educational curriculum, learners should be better able to: 1. Review the role of bispecific antibodies in the current treatment landscape of relapsed/refractory (R/R) multiple myeloma (MM); 2. Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated R/R MM; 3. Describe strategies to optimize outcomes with bispecific antibodies for the treatment of R/R MM; and 4. Outline practical considerations for incorporating bispecific antibodies into the treatment of heavily pretreated R/R MM in the community setting.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/GPV
- Start Date: 2024-12-30 06:00:00
- End Date: 2024-12-30 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Regeneron Pharmaceuticals, Inc. - Amount: 170490.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all